Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene

American Journal of Pathology

Volumn 183, Issue 3, 2013, Pages 938-950

  Steagall, Wendy K ^a   Pacheco Rodriguez, Gustavo ^a   Glasgow, Connie G ^a   Ikeda, Yoshihiko ^a   Lin, Jing Ping ^a   Zheng, Gang ^a   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; OSTEOPROTEGERIN RECEPTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SYNDECAN 1; SYNDECAN 2; TUBERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EXPLANT; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LUNG NODULE; LUNG PARENCHYMA; LYMPHANGIOLEIOMYOMATOSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SMOOTH MUSCLE FIBER; TSC2 TUMOR SUPPRESSOR GENE; TUMOR SUPPRESSOR GENE;

ADULT; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CCL2; FLOW CYTOMETRY; GP100 MELANOMA ANTIGEN; HEALTHY VOLUNTEERS; HUMANS; LOSS OF HETEROZYGOSITY; LUNG; LYMPHANGIOLEIOMYOMATOSIS; MICRODISSECTION; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOPROTEGERIN; RECEPTORS, CELL SURFACE; TUMOR SUPPRESSOR PROTEINS;

EID: 84883192290     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.05.024     Document Type: Article

References (66)

1. M. Schoppet, K.T. Preissner, and L.C. Hofbauer RANK ligand and osteoprotegerin paracrine regulators of bone metabolism and vascular function Arterioscler Thromb Vasc Biol 22 2002 549 553
2. A.P. Trouvin, and V. Göeb Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss Clin Interv Aging 5 2010 345 354
3. S. Jurado, X. Nogues, L. Agueda, N. Garcia-Giralt, R. Urreizti, G. Yoskovitz, L. Perez-Edo, G. Salo, R. Carreras, L. Mellibovsky, S. Balcells, D. Grinberg, and A. Diez-Perez Polymorphisms and haplotypes across the osteoprotegerin gene associated with bone mineral density and osteoporotic fractures Osteoporos Int 21 2010 287 296
4. J.B. Richards, F. Rivadeneira, M. Inouye, T.M. Pastinen, N. Soranzo, S.G. Wilson, T. Andrew, M. Falchi, R. Gwilliam, K.R. Ahmadi, A.M. Valdes, P. Arp, P. Whittaker, D.J. Verlaan, M. Jhamai, V. Kumanduri, M. Moorhouse, J.B. van Meurs, A. Hofman, H.A.P. Pols, D. Hart, G. Zhai, B.S. Kato, B.H. Mullin, F. Zhang, P. Deloukas, A.G. Uitterlinden, and T.D. Spector Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study Lancet 371 2008 1505 1512
5. C. Vidal, R. Formosa, and A. Xuereb-Anastasi Functional polymorphisms within the TNFRSF11B (osteoprotegerin) gene increase the risk for low bone mineral density J Mol Endocrinol 47 2011 327 333
6. U. Styrkarsdottir, B.V. Halldorsson, S. Gretarsdottir, D.F. Gudbjartsson, G.B. Walters, T. Ingvarsson, T. Jonsdottir, J. Saemundsdottir, J.R. Center, T.V. Nguyen, Y. Bagger, J.R. Gulcher, J.A. Eisman, C. Christiansen, G. Sigurdsson, A. Kong, U. Thorsteinsdottir, and K. Stefansson Multiple genetic loci for bone mineral density and fractures N Engl J Med 358 2008 2355 2365
7. G. Brunetti, F. Marzano, S. Colucci, A. Ventura, L. Cavallo, M. Grano, and M.F. Faienza Genotype-phenotype correlation in Juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene Endocrine 42 2012 266 271
8. N. Bucay, I. Sarosi, C.R. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H.L. Tan, W. Xu, D.L. Lacey, W.J. Boyle, and W.S. Simonet Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 1998 1260 1268
9. S. Jono, Y. Ikari, A. Shioi, K. Mori, T. Miki, K. Hara, and Y. Nishizawa Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease Circulation 106 2002 1192 1194
10. D. Tousoulis, G. Siasos, K. Maniatis, R. Oikonomou, S. Kioufis, M. Zaromitidou, T. Paraskevopoulos, S. Michalea, C. Kollia, A. Miliou, E. Kokkou, A.G. Papavassiliou, and C. Stefanadis Serum osteoprotegerin and osteopontin levels are associated with arterial stiffness and the presence and severity of coronary artery disease Int J Cardiol 2012 http://dx.doi.org/10.1016/j.ijcard. 2012.05.001
11. S.M. Venuraju, A. Yerramasu, R. Corder, and A. Lahiri Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity J Am Coll Cardiol 55 2010 2049 2061
12. K. Yano, E. Tsuda, N. Washida, F. Kobayashi, M. Goto, A. Harada, K. Ikeda, K. Higashio, and Y. Yamada Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increase serum concentrations in postmenopausal women with osteoporosis J Bone Miner Res 14 1999 518 527
13. F. Corallini, A. Gonelli, F. D'Aurizio, M.G. di Iasio, and M. Vaccarezza Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin Eur J Histochem 53 2009 19 24
14. A. Lawrie, E. Waterman, M. Southwood, D. Evans, J. Suntharalingam, S. Francis, D. Crossman, P. Croucher, N. Morrell, and C. Newman Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary artery hypertension Am J Pathol 172 2008 256 264
15. V integrin in osteoprotegerin-induced endothelial cell migration and proliferation Microvasc Res 76 2008 139 144
16. B.A. Mosheimer, N.C. Kaneider, C. Feistritzer, A.M. Djanani, D.H. Sturn, J.R. Patsch, and C.J. Wiedermann Syndecan-1 is involved in osteoprotegerin- induced chemotaxis in human peripheral blood monocytes J Clin Endocrinol Metab 90 2005 2964 2971
17. I. Holen, and C.M. Shipman Role of osteoprotegerin (OPG) in cancer Clin Sci 110 2006 279 291
18. G. Zauli, E. Melloni, S. Capitani, and P. Secchiero Role of full-length osteoprotegerin in tumor cell biology Cell Mol Life Sci 66 2009 841 851
19. H.L. Neville-Webbe, N.A. Cross, C.L. Eaton, R. Nyambo, C.A. Evans, and R.E. Coleman Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis Breast Cancer Res Treat 86 2004 269 279
20. R. Nyambo, N.A. Cross, J.M. Lippitt, I. Holen, G. Bryden, F.C. Hamdy, and C.L. Eaton Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis J Bone Miner Res 10 2004 1712 1721
21. C.M. Shipman, and P.I. Croucher Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells Cancer Res 63 2003 912 916
22. E.N. De Toni, S.E. Thieme, A. Herbst, A. Behrens, P. Stieber, A. Jung, H. Blum, B. Goke, and F.T. Kolligs OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer Clin Cancer Res 14 2008 4713 4718
23. I. Holen, P.I. Croucher, F.C. Hamdy, and C.L. Eaton Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells Cancer Res 62 2002 1619 1623
24. A. Lipton, S.M. Ali, K. Leitzel, V. Chinchilli, L. Witters, L. Engle, D. Holloway, P. Bekker, and C.R. Dunstan Serum osteoprotegerin levels in healthy controls and cancer patients Clin Cancer Res 8 2002 2306 2310
25. J.M. Brown, R.L. Vessella, P.J. Kostenuik, C.R. Dunstan, P.H. Lange, and E. Corey Serum osteoprotegerin levels are increased in patients with advanced prostate cancer Clin Cancer Res 10 2001 2977 2983
26. Y. Mizutani, H. Matsubara, K. Yamamoto, Y. Nan Li, K. Mikami, K. Okihara, A. Kawauchi, B. Bonavida, and T. Miki Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma Cancer 101 2004 1794 1802
27. R. Ito, H. Nakayama, K. Yoshida, K. Kuraoka, J. Motoshita, N. Oda, N. Oue, and W. Yasui Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma Virchows Arch 443 2003 146 151
28. U. Malyankar, M. Scatena, K. Suchland, T. Yun, E. Clark, and C. Giachelli Osteoprotegerin is an αvβ3-induced, NF-κΒ-dependent survival factor for endothelial cells J Biol Chem 275 2000 20959 20962
29. S.S. Cross, Z. Yang, N.J. Brown, S.P. Balasubramanian, C.A. Evans, J.K. Woodward, H.L. Neville-Webbe, J.M. Lippitt, M.W. Reed, R.E. Coleman, and I. Holen Osteoprotegerin (OPG): a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis Int J Cancer 118 2006 1901 1908
30. K.A. Orlova, and P.B. Crino The tuberous sclerosis complex Ann N Y Acad Sci 1184 2010 87 105
31. W.K. Steagall, A.M. Taveira-DaSilva, and J. Moss Clinical and molecular insights into lymphangioleiomyomatosis Sarcoidosis Vasc Diffuse Lung Dis 22 Suppl 2005 S49 S66
32. T. Carsillo, A. Astrinidis, and E.P. Henske Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis Proc Natl Acad Sci U S A 97 2000 6085 6090
33. D.M. Crooks, G. Pacheco-Rodriguez, R.M. DeCastro, J.P. McCoy Jr., J.A. Wang, F. Kumaki, T. Darling, and J. Moss Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis Proc Natl Acad Sci U S A 101 2004 17462 17467
34. X. Cai, G. Pacheco-Rodriguez, Q.-Y. Fan, M. Haughey, L. Samsel, S. El-Chemaly, H.-P. Wu, J.P. McCoy, W.K. Steagall, J.-P. Lin, T.N. Darling, and J. Moss Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis Am J Respir Crit Care Med 182 2010 1410 1418
35. G.J. Adema, A.J. de Boer, R. van't Hullenaar, M. Denijn, D.J. Ruiter, A.M. Vogel, and C.G. Figdor Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA Am J Pathol 143 1993 1579 1585
36. -/- cells Lymphat Res Biol 8 2010 59 69
37. V.J. Ferrans, Z.-X. Yu, W.K. Nelson, J.C. Valencia, A. Tatsuguchi, N.A. Avila, W. Riemenschn, K. Matsui, W.D. Travis, and J. Moss Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features J Nippon Med Sch 67 2000 311 329
38. Y. Matsumoto, K. Horiba, J. Usuki, S.C. Chu, V.J. Ferrans, and J. Moss Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis Am J Respir Cell Mol Biol 21 1999 327 336
39. G. Pacheco-Rodriquez, W.K. Steagall, D.M. Crooks, L.A. Stevens, H. Hashimoto, S. Li, J.A. Wang, T.N. Darling, and J. Moss TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis Cancer Res 67 2007 10573 10581
40. Y. Ikeda, A.M. Taveira-DaSilva, G. Pacheco-Rodriguez, W.K. Steagall, S. El-Chemaly, B.R. Gochuico, R.M. May, O.M. Hathaway, S. Li, J.A. Wang, T.N. Darling, M. Stylianou, and J. Moss Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2 Am J Physiol Lung Cell Mol Physiol 300 2011 L64 L72
41. G. Pacheco-Rodriguez, F. Kumaki, W.K. Steagall, Y. Zhang, Y. Ikeda, J.-P. Lin, E.M. Billings, and J. Moss Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene J Immunol 182 2009 1270 1277
42. A. Hikita, and S. Tanaka Ectodomain shedding of receptor activator of NF-kappaB ligand Adv Exp Med Biol 602 2007 15 21
43. T. Nakashima, Y. Kobayashi, S. Yamasaki, A. Kawakami, K. Eguchi, H. Sasaki, and H. Sakai Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines Biochem Biophys Res Commun 275 2000 768 775
44. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.-P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, C.A. Smith, and R.G. Goodwin Identification and characterization of a new member of the TNF family that induces apoptosis Immunity 3 1995 673 682
45. rd, E.J. Atkinson, W.M. O'Fallon, C. Dunstan, and B.L. Riggs Correlates of osteoprotegerin levels in women and men Osteoporos Int 13 2002 394 399
46. I. Pantsulaia, S. Trofimov, E. Kobyliansky, and G. Livshits Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees Cytokine 32 2005 117 123
47. I. Bittmann, B. Rolf, G. Amann, and U. Lohrs Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis Hum Pathol 34 2003 95 98
48. M. Karbowniczek, A. Astrinidis, B.R. Balsara, J.R. Testa, J.H. Lium, T.V. Colby, F.X. McCormack, and E.P. Henske Recurrent lymphangioleiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism Am J Respir Crit Care Med 167 2003 976 982
49. S. Fili, M. Karalaki, and B. Schaller Mechanism of bone metastasis: the role of osteoprotegerin and of host-tissue microenvironment-related survival factors Cancer Lett 283 2009 10 19
50. E.A. Ross, S. Freeman, Y. Zhao, T.S. Dhanjal, E.J. Ross, S. Lax, Z. Ahmed, T.Z. Hou, N. Kalia, S. Egginton, G. Nash, S.P. Watson, J. Frampton, and C.D. Buckley A novel role for PECAM-1 (CD31) in regulating haematopoietic progenitor cell compartmentalization between the peripheral blood and bone marrow PLoS One 3 2008 e2338
51. S.-J. Kim, J.-S. Kim, J. Papadopoulos, S.W. Kim, M. Maya, F. Zhang, J. He, D. Fan, R. Langley, and I.J. Fidler Circulating monocytes expressing CD31 implications for acute and chronic angiogenesis Am J Pathol 174 2009 1972 1980
52. J.K. McKenney, S.W. Weiss, and A.L. Folpe CD31 expression in intratumoral macrophages a potential diagnostic pitfall Am J Surg Pathol 25 2001 1167 1173
53. X. Zhang, and W.D. Travis Pulmonary lymphangioleiomyomatosis Arch Pathol Lab Med 134 2010 1823 1828
54. M. Karbowniczek, J. Yu, and E.P. Henske Renal angiomyolipomas from patients with sporadic lymphangioleiomyomatosis contain both neoplastic and non-neoplastic vascular structures Am J Pathol 162 2003 491 500
55. J.C. Valencia, G. Pacheco-Rodriguez, A.K. Carmona, J. Xavier, P. Bruneval, W.K. Riemenschneider, Y. Ikeda, Z.-X. Yu, V.J. Ferrans, and J. Moss Tissue-specific renin-angiotensin system in pulmonary lymphangioleiomyomatosis Am J Respir Cell Mol Biol 35 2006 40 47
56. J.C. Valencia, K. Matsui, C. Bondy, J. Zhou, A. Rasmussen, K. Cullen, Z.X. Yu, J. Moss, and V.J. Ferrans Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis J Investig Med 49 2001 421 433
57. E. Lesma, V. Grande, S. Carelli, D. Brancaccio, M.P. Canevini, R.M. Alfano, G. Coggi, A.M. DiGiulio, and A. Gorio Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma Am J Pathol 167 2005 1093 1103
58. M.-J. Kwon, B. Jang, J.Y. Yi, I.-O. Han, and E.S. Oh Syndecans play dual roles as cell adhesion receptors and docking receptors FEBS Lett 586 2012 2207 2211
59. A.C.W. Zannettino, C.A. Holding, P. Diamond, G.J. Atkins, P. Kostakis, A. Farrugia, J. Gamble, L.B. To, D.M. Findlay, and D.R. Haynes Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor J Cell Physiol 204 2005 714 723
60. J. Yu, and E.P. Henske mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis Lymphat Res Biol 8 2010 43 49
61. 2) modulates cytokine and chemokine expression in human monocyte-derived cells Blood 104 2004 1404 1410
62. A.M. Taveira-DaSilva, M.P. Stylianou, C.J. Hedin, O. Hathaway, and J. Moss Bone mineral density in lymphangioleiomyomatosis Am J Respir Crit Care Med 171 2005 61 67
63. A. Taveira-DaSilva, O.M. Hathaway, V. Sachdev, Y. Shizukuda, C.W. Birdsall, and J. Moss Pulmonary artery pressure in lymphangioleiomyomatosis Chest 132 2007 1573 1578
64. S. Kudlacek, B. Schneider, W. Woloszczuk, P. Pietschmann, and R. Willvonseder Serum levels of osteoprotegerin increase with age in a healthy adult population Bone 32 2003 681 686
65. D. Wagner, and A. Fahrleitner-Pammer Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help? Wien Med Wochenschr 160 2010 452 457
66. P.E. Reid, J. Brown, and I. Holen Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact Mol Cancer 8 2009 49 58